CD164 and FCRL3 are highly expressed on CD4+CD26- T cells in sézary syndrome patients

Maria Wysocka, Andrew V. Kossenkov, Bernice M. Benoit, Andrea B. Troxel, Elisha Singer, Andras Schaffer, Brian Kim, Tzvete Dentchev, Satoshi Nagata, Tomoko Ise, Louise C. Showe, Alain H. Rook

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


Sézary syndrome (SS) cells express cell surface molecules also found on normal activated CD4 T cells. In an effort to find a more specific surface marker for malignant SS cells, a microarray analysis of gene expression was performed. Results showed significantly increased levels of mRNA for CD164, a sialomucin found on human CD34+ hematopoietic stem cells, and FCRL3, a molecule present on a subset of human natural T regulatory cells. Both markers were increased in CD4 T cells from SS patients compared with healthy donors (HD). Flow cytometry studies confirmed the increased expression of CD164 and FCRL3 primarily on CD4+CD26- T cells of SS patients. Importantly, a statistically significant correlation was found between an elevated percentage of CD4+CD164+ T cells and an elevated percentage of CD4+CD26- T cells in all tested SS patients but not in patients with mycosis fungoides and atopic dermatitis or HD. FCRL3 expression was significantly increased only in patients with high tumor burden. CD4+CD164+ cells displayed cerebriform morphology and their loss correlated with clinical improvement in treated patients. Our results suggest that CD164 can serve as a marker for diagnosis and for monitoring progression of cutaneous T-cell lymphoma (CTCL)/SS and that FCRL3 expression correlates with a high circulating tumor burden.

Original languageEnglish
Pages (from-to)229-236
Number of pages8
JournalJournal of Investigative Dermatology
Issue number1
StatePublished - Jan 2014


Dive into the research topics of 'CD164 and FCRL3 are highly expressed on CD4+CD26- T cells in sézary syndrome patients'. Together they form a unique fingerprint.

Cite this